“The Dogs of the Dow” system involves purchasing the index’s 10 stocks with the highest dividend yields at the end of each year. Using the technique has a few major advantages. Of course, stocks with high dividend yields pay investors to wait for a rebound to provide either significant income or the ability to buy more shares of stock at no extra cost. Moreover, for the most part, the members of the Dow are profitable leaders in their sectors, so they pose little risk. The members with the highest dividend ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Key PointsAmgen is up +6% so far and is the Nasdaq-100’s second best performing stock year-to-date.At 20x this year’s projected earnings, Regeneron may still be one of the best values in biotech.Gilead Sciences has gone sideways for the better part of the last five years but ended 2023 on an upswing that may have staying power.5 stocks we like better than AmgenUp 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It’s very early, but the sect ...

Amgen Inc. (NASDAQ:AMGN) J.P. Morgan 42nd Annual Healthcare Conference 2024 January 8, 2024 ET Company Participants Robert Bradway - Chairman & CEO Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good morning, everybody. I'm Chris Schott at J.P. Morgan, and it's my pleasure to be introducing Amgen today. From the company, we have Bob Bradway, the company's Chairman and CEO. Obviously, a very productive 2023 for the company and really looking forward to Bob's comments as we think about t ...

Amgen Inc. (NASDAQ:AMGN) J.P. Morgan 42nd Annual Healthcare Conference 2024 January 8, 2024 ET Company Participants Robert Bradway - Chairman & CEO Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good morning, everybody. I'm Chris Schott at J.P. Morgan, and it's my pleasure to be introducing Amgen today. From the company, we have Bob Bradway, the company's Chairman and CEO. Obviously, a very productive 2023 for the company and really looking forward to Bob's comments as we think about t ...

Nvidia Corp. NVDA, +4.83% is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships Monday with Amgen Inc. AMGN, +1.35% and Recursion Pharmaceuticals Inc. RXRX, +3.65%. Amgen subsidiary deCODE Genetics is building out an Nvidia supercomputer to create genomics “foundation models” — models trained on massive datasets to tackle a variety of jobs — to fuel drug discovery, Nvidia said Monday at the JPMorgan Chase & Co. JPM, -1.50% healthcare conference ...

Amgen (AMGN) closed at $303.17 in the latest trading session, marking a +0.82% move from the prior day. This move outpaced the S&P 500's daily loss of 0.34%. Elsewhere, the Dow gained 0.03%, while the tech-heavy Nasdaq lost 0.56%.Shares of the world's largest biotech drugmaker witnessed a gain of 11.64% over the previous month, beating the performance of the Medical sector with its gain of 5.72% and the S&P 500's gain of 2.56%.The upcoming earnings release of Amgen will be of great interest to investors. Th ...

Firn Foreword While two-thirds of this collection of Dow Industrials (DJI) is too pricey and reveals only skinny dividends, two of the five lowest-priced Dogs of the Dow are ready to buy. This month, Verizon Communications Inc. (VZ), and Walgreens Boots Alliance (WBA) live up to the dogcatcher ideal of annual dividends from $1K invested exceeding their single share prices. However, six more, Dow Inc. (DOW), Cisco Systems (CSCO), Coca-Cola Co (KO), 3M Co (MMM), Chevron (CVX), and International Business Machi ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines today announced key advancements across its clinical pipeline and generative AI platform, including its first patient dosed in GB-0895, progress in the phase 1 study for GB-0669, and an expansion of its collaboration agreement with Amgen. Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthca ...

It’s a new year and apparently there’s a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024. But stodgy, dividend-paying consumer staples, telecom, and healthcare stocks are surging.Coca-Cola (NYSE:KO) was in the green on Tuesday and Wednesday while the broader market fell both days. Coke, a Dow Jones stock, is already up 2% after tumbling about 5% in 2023, missing the big market rally. The soft drink giant, whic ...